IP Library Granted Patent US 9,884,825
Granted Patent B2
US 9,884,825 · App. 14/418,025 · Granted Feb 6, 2018

Curcumin analogs and methods of making and using thereof

Inventors: Diwan S. Rawat (Delhi, IN); Binghe Wang (Marietta, GA); Nitin Kumar (Delhi, IN); Sunny Manohar (Delhi, IN); Xiaochuan Yang (Towson, MD); Guojing Sun (Atlanta, GA); Nanting Ni (Ventura, CA)
Assignees: Georgia State University Research Foundation, Inc.; University of Delhi
C07D213/68C07C49/753C07C225/18C07D213/89C07D233/61C07D295/116C07D401/06C07D401/14C07C2601/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,884,825
App. No.
14/418,025
Granted
Feb 6, 2018
Kind
B2
Abstract

Compounds having Formula I or II, and methods of making and using thereof, are described herein:

Claims (38)

1. A compound of Formula II:

wherein, R 1 , R 2 , R 4 , R 5 , R 6 , R 7 , R 9 , and R 10 are independently absent or selected from the group consisting of substituted or unsubstituted, linear, branched, or cyclic alkyl, alkenyl, or alkynyl, halogen, substituted or unsubstituted aryl or heteroaryl, substituted or unsubstituted alkoxy, hydroxy, cyano, formyl, acyl, carboxylic acid, carboxylate, primary amide, secondary amide, tertiary amide, secondary carbamate, tertiary carbamate, urea, carbinol, ester, thiol, primary amine, secondary amine, tertiary amine, thioether, sulfinyl group, sulfonyl group;

wherein, n=0, 2, 3, or 4;

R 3 and R 8 are —O(CH 2 ) m X, wherein m is an integer from 0-10 and X is a halogen, or an aromatic or non-aromatic heterocyclic ring selected from the group consisting of:

wherein

each occurrence of R is independently absent or selected from the group consisting of substituted or unsubstituted, linear, branched, or cyclic alkyl, alkenyl, or alkynyl, halogen, substituted or unsubstituted aryl or heteroaryl, substituted or unsubstituted alkoxy, hydroxy, cyano, formyl, acyl, carboxylic acid, carboxylate, primary amide, secondary amide, tertiary amide, secondary carbamate, tertiary carbamate, urea, carbinol, ester, thiol, primary amine, secondary amine, tertiary amine, thioether, sulfinyl group, sulfonyl group;

T is O, S, or NR 13 , wherein each occurrence of R 13 is independently absent or selected from the group consisting of substituted or unsubstituted, linear, branched, or cyclic alkyl, alkenyl, or alkynyl; halogen, substituted or unsubstituted aryl or heteroaryl; substituted or unsubstituted alkoxy; hydroxy, cyano, formyl, acyl, carboxylic acid, carboxylate, primary amide, secondary amide, tertiary amide, secondary carbamate, tertiary carbamate, urea, carbinol, ester, thiol, primary amine, secondary amine, tertiary amine, thioether, sulfinyl group, sulfonyl group; and

z, as valence permits, is an integer from 0-10.

2. The compound of claim 1 , wherein at least one of R 1 -R 2 , R 4 -R 5 and at least one of R 6 -R 7 , R 9 -R 10 are halogen.

3. The compound of claim 1 , wherein at least one of R 1 , R 2 , R 4 , or R 5 and at least one of R 6 , R 7 , R 9 , or R 10 are unsubstituted alkyl.

4. The compound of claim 1 , wherein at least one of R 1 , R 2 , R 4 , or R 5 and at least one of R 6 , R 7 , R 9 , or R 10 are unsubstituted alkoxy.

5. The compound of claim 1 , wherein n is 2 or 3; and R 2 and R 9 are other than hydrogen.

6. The compound of claim 5 , wherein R 2 and R 9 are lower alkoxy groups.

7. The compound of claim 1 , wherein the compound is:

8. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

9. The composition of claim 8 , wherein the carrier is suitable for enteral administration.

10. The composition of claim 9 , wherein the carrier is suitable for oral administration.

11. The composition of claim 10 , wherein the composition is the form of a tablet, soft capsule, hard capsule, caplet, solution, or suspension.

12. The composition of claim 8 , wherein the carrier is suitable for parenteral administration.

13. The composition of claim 12 , wherein the composition is in the form of a solution or suspension.

14. A method of treating a proliferative disorder in a patient in need thereof, the method comprising administering one or more compounds of claim 1 .

15. The method of claim 14 , wherein the proliferative disorder is cancer.

16. The compound of claim 5 , wherein R 2 , R 9 , or both are methoxy.

17. A compound, wherein the compound is:

18. A compound of Formula I:

wherein, L comprises a sulfonyl or substituted heteroaryl group,

wherein, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are independently absent or selected from the group consisting of substituted or unsubstituted, linear, branched, or cyclic alkyl, alkenyl, or alkynyl, halogen, substituted or unsubstituted aryl or heteroaryl, substituted or unsubstituted alkoxy, hydroxy, cyano, formyl, acyl, carboxylic acid, carboxylate, primary amide, secondary amide, tertiary amide, secondary carbamate, tertiary carbamate, urea, carbinol, ester, thiol, primary amine, secondary amine, tertiary amine, thioether, sulfinyl group, sulfonyl group;

wherein, R 11 is substituted or unsubstituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, or alkynyl, substituted or unsubstituted benzyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl;

with the proviso that:

(a) when L comprises a sulfonyl, and R 11 is substituted with a halogen, R 3 and R 8 are independently linear, branched, or cyclic alkyl, alkenyl, or alkynyl, substituted or unsubstituted aryl or heteroaryl, substituted or unsubstituted alkoxy, hydroxy, cyano, formyl, acyl, carboxylic acid, carboxylate, primary amide, secondary amide, tertiary amide, secondary carbamate, tertiary carbamate, urea, carbinol, ester, thiol, primary amine, secondary amine, tertiary amine, thioether, sulfinyl group, sulfonyl group;

(b) when L comprises a sulfonyl, and R 11 is substituted with an alkoxy, R 4 and R 7 are independently substituted or unsubstituted, linear, branched, or cyclic alkyl, alkenyl, or alkynyl, halogen, substituted or unsubstituted aryl or heteroaryl, substituted or unsubstituted alkoxy, hydroxy, cyano, formyl, acyl, carboxylic acid, carboxylate, primary amide, secondary amide, tertiary amide, secondary carbamate, tertiary carbamate, urea, carbinol, ester, thiol, primary amine, secondary amine, tertiary amine, thioether, sulfinyl group, sulfonyl group; or

(c) when L comprises a sulfonyl, and R 11 is substituted with an alkyl, R 1 , R 10 , or both, are not halogen.

19. The compound of claim 18 , wherein:

L is a sulfonyl group, and

R 11 is substituted or unsubstituted alkyl, cycloalkyl, alkenyl, cycloalkenyl, or alkynyl, substituted or unsubstituted benzyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl.

20. The compound of claim 18 , wherein L comprises a substituted heteroaryl group.

21. The compound of claim 20 , wherein the substituted heteroaryl group is a substituted triazole.

22. A compound having the formula:

Assignments (1)
CONFIRMATORY LICENSE Recorded Aug 19, 2015
From: GEORGIA STATE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 036395/0538 →
Continuity (2)
Provisional Application 61679233 · Aug 3, 2012
Related Publication 20150152056A1 · Jun 4, 2015